Table 1. Demographics and clinicopathologic characteristics of GBM patients in the TCGA training cohort and CGGA validation cohort based on the autophagy signature.
| Variables | TCGA (Training set) | CGGA Batch 1 (Validation set-1) | CGGA Batch 2 (Validation set-2) | ||||||
| Total (n=155) | Low risk (n=78) | High risk (n=77) | Total (n=83) | Low risk (n=42) | High risk (n=41) | Total (n=133) | Low risk (n=67) | High risk (n=66) | |
| Age | |||||||||
| <= 50 years | 38 | 24 | 14 | 40 | 22 | 18 | 54 | 28 | 26 |
| > 50 years | 117 | 54 | 63 | 43 | 20 | 23 | 79 | 39 | 40 |
| Sex | |||||||||
| Female | 54 | 26 | 28 | 32 | 19 | 13 | 54 | 29 | 25 |
| Male | 101 | 52 | 49 | 51 | 23 | 28 | 79 | 38 | 41 |
| New event | |||||||||
| None or NA | 66 | 30 | 36 | NA | NA | ||||
| Yes | 89 | 48 | 41 | NA | NA | ||||
| KPS | |||||||||
| < 80 | 33 | 19 | 14 | NA | NA | ||||
| >= 80 | 83 | 41 | 42 | NA | NA | ||||
| NA | 39 | 18 | 21 | NA | NA | ||||
| Pharmaceutical therapy | |||||||||
| CT only | 65 | 34 | 31 | 23 (No) | 8 | 15 | 17 (No) | 11 | 6 |
| CT + TMT | 27 | 13 | 14 | 57 (Yes) | 32 | 25 | 111(Yes) | 54 | 57 |
| CT + HT | 21 | 14 | 7 | 3 (NA) | 2 | 1 | 5 (NA) | 2 | 3 |
| Others | 5 | 4 | 1 | - | - | ||||
| No or NA | 37 | 13 | 24 | - | - | ||||
| Radiation therapy | |||||||||
| No | 23 | 7 | 16 | 10 | 6 | 4 | 17 | 9 | 7 |
| Yes | 125 | 66 | 59 | 70 | 34 | 36 | 113 | 56 | 57 |
| NA | 7 | 5 | 2 | 3 | 2 | 1 | 4 | 2 | 2 |
| Surgery | |||||||||
| Biopsy only | 16 | 10 | 6 | NA | NA | ||||
| Tumor resection | 139 | 68 | 71 | NA | NA | ||||
| IDH status | |||||||||
| Wildtype | 147 | 70 | 77 | 72 | 33 | 39 | 103 | 50 | 53 |
| Mutant | 8 | 8 | 0 | 11 | 9 | 2 | 30 | 17 | 13 |
| 1p/19q status | |||||||||
| Non-codeletion | NA | 82 | 41 | 41 | 103 | 63 | 40 | ||
| Codeletion | NA | 0 | 0 | 0 | 5 | 4 | 1 | ||
| NA | NA | 1 | 1 | 0 | 25 | 0 | 25 | ||
NA, not available; KPS, Karnofsky performance score; CT, chemotherapy; TMT, targeted molecular therapy; HT, hormone therapy.
“New event” included progression and recurrence. “Others” in pharmaceutical therapy included CT + TMT + HT, CT + TMT + Immunotherapy, and CT + Immunotherapy.